GCEngine platform provides a comprehensive ncAA incorporation in vivo applications service, designed for preclinical research (RUO; non-GMP). The service builds upon orthogonal tRNA/aaRS pairs to enable ncAA incorporation in bacterial, yeast, and mammalian cells. This service offers host-specific optimization and applications in drug development, protein engineering, and functional assays. By balancing efficiency, fidelity, and background suppression, we provide a robust platform for customized protein design and molecular research. Codon strategies include UAG amber and, where supported by the host and components, quadruplet or engineered sense-codon reassignment.
ncAA incorporation in vivo enables the introduction of non-canonical amino acids (ncAAs) at specific sites within proteins in living cells. By using orthogonal tRNA/aaRS pairs, codons like UAG or quadruplet codons are reassigned to incorporate ncAAs, unlocking new protein functionalities such as photo-crosslinking, bioorthogona chemistry, and targeted labeling. This technique is applicable across various hosts, including E. coli, yeast, and mammalian cells, with optimizations tailored to each system's expression and ncAA uptake. The process is widely used in drug development, protein engineering, and functional assays, providing tools for precise molecular manipulation, pathway analysis, and advanced therapeutic design.
The ncAA incorporation in vivo applications service includes in vivo verification, host-specific optimization, and application-specific strategies. Our protocols are tailored to the system used (E. coli, yeast, or mammalian cells), ensuring high-efficiency incorporation and minimal background. The service is applicable to protein labeling, crosslinking, bioorthogonal chemistry, and drug development applications.
In Vivo Validation
We perform in vivo assays to verify site-specific ncAA incorporation using matched controls and standardized reporters. This involves dose–response studies to optimize the concentration of ncAA for maximum incorporation with minimal background. We employ quantitative reporters such as fluorescence, Western blot analysis, and flow cytometry to confirm protein expression and validate the functionality of the incorporated ncAA in the host system.
Host-Specific Optimization
For each host (E.coli, yeast, or mammalian), we optimize protocols to ensure maximum ncAA incorporation efficiency. In E. coli, we optimize strain background (e.g., RF1-attenuated), induction, copy number, and codon context. For yeast and mammalian systems, we refine transfection conditions, promoter strengths, and ncAA uptake/formulation (e.g., prodrugs or transporter co-expression) to enhance yield and functionality.
Applications in Drug Development
Incorporating ncAAs in vivo enables powerful applications in drug development. These include site-specific conjugates for antibody-drug conjugates (ADCs), radiolabeling proteins for imaging, and photo-activable proteins for targeted studies. This service also supports discovery and preclinical research—including protein–protein interaction assays, enzymatic activity mapping, and mechanism-of-action studies—without implying clinical manufacture or use.
Protein Engineering and Functional Assays
Our service facilitates protein engineering applications such as bioorthogonal chemistry, photocrosslinking/photocontrol, interaction mapping, and proteomics. Additionally, crosslinking studies allow for the investigation of protein interactions and the creation of custom probes for studying complex biomolecular pathways. These techniques can be applied to biotech, pharma, and synthetic biology applications , opening new avenues in protein function and pathway analysis.
Bring your ncAA projects to life with optimized in vivo incorporation and functional assays. Whether in drug development, protein engineering, or synthetic biology, GCEngine platform can help you achieve your goals with precision. Contact us today to start developing your customized plan, timelines, and formal quote for successful implementation across multiple hosts.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.